DENVER, March 18 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation , a worldwide developer and marketer of diagnostic test kits, has executed a licensing agreement with the Okayama Prefecture Industrial Promotion Foundation covering new diagnostic technology for serum amyloid protein (SAP), an important serum bio-marker for cardiovascular inflammation. The technology was developed by Dr. Eiji Matsuura at the University of Okayama Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Corgenix has had strategic alliances with researchers and academic institutions in Okayama, Japan, since 2001. The Company’s patented AtherOx(TM) technology was developed in collaboration with researchers from the University of Okayama. This new agreement opens additional avenues of technology and strengthens the collaboration with the Okayama Prefecture (a prefecture is the equivalent of a state) aimed at developing innovative and important diagnostic products in the future.
“We are pleased to expand our collaborative relationships in this region. Our alliances have already produced several exciting products, and gaining access to the SAP technology is very promising for our Company,” said Douglass Simpson, Corgenix President and Chief Executive Officer. “Serum amyloid proteins are stress proteins typically elevated in bacterial and viral infections, and have been shown to be related to cardiovascular disease as well.”
The agreement with Corgenix is the first one established between the Okayama Prefecture Industrial Promotion Foundation -- a government agency promoting research and development among industry, universities and governments -- and a U.S. company. Under the terms of the agreement, Corgenix has the exclusive rights outside of Japan to further develop the serum amyloid technology, including adapting to research and clinical diagnostic products.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for vascular diseases, immunology disorders, and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 52 diagnostic products through a global distribution. More information is available at http://www.corgenix.com.
Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
CONTACT: William Critchfield, Senior VP and CFO of Corgenix Medical
Corporation, +1-303-453-8903, wcritchfield@corgenix.com; or media, Dan
Snyders, Vice President, Public Relations Supervisor of Armada Medical
Marketing, +1-303-623-1190, ext. 230, fax, +1-303-623-1191,
dan@armadamedical.com, for Corgenix Medical Corporation
Web site: http://www.corgenix.com/
